Astria Therapeutics Soars 11.79% on Positive Trial Results

On June 13, 2025, Astria Therapeutics' stock surged by 11.79% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Astria Therapeutics recently announced positive initial results from the ALPHA-SOLAR long-term open-label trial of navenibart for hereditary angioedema (HAE). The results showed a robust overall reduction in the monthly attack rate, with a 92% mean and 97% median reduction. These findings further support the favorable safety and efficacy profile of navenibart, which has been a key focus for the company.

In addition to the ALPHA-SOLAR trial, Astria Therapeutics has also reported positive results from another HAE drug trial. The company has made significant progress in its clinical development programs, which has contributed to the positive market sentiment surrounding the stock.

Furthermore, Astria Therapeutics announced positive initial proof-of-concept results from the ALPHA-STAR Phase 1b/2 trial of STAR-0215 for HAE. These results provide additional validation for the company's pipeline and its commitment to developing innovative therapies for rare diseases.

Overall, the recent clinical trial results and corporate updates from Astria Therapeutics have been well-received by the market, contributing to the stock's strong performance. Investors are optimistic about the company's prospects and its potential to deliver meaningful therapies for patients with rare diseases.